PMID- 33001355
OWN - NLM
STAT- MEDLINE
DCOM- 20211104
LR  - 20221207
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 21
IP  - 3
DP  - 2021 May
TI  - Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in 
      Patients with Heart Failure: A Meta-Analysis.
PG  - 321-330
LID - 10.1007/s40256-020-00441-x [doi]
AB  - BACKGROUND: Several clinical trials of dapagliflozin in patients with type 2 
      diabetes mellitus (T2DM) at elevated cardiovascular risk have observed reduced 
      hospitalization for heart failure (HHF). Several studies have also suggested 
      cardiovascular benefits for patients with HF regardless of whether or not they 
      have T2DM. OBJECTIVE: This meta-analysis was conducted to evaluate the 
      therapeutic effects of dapagliflozin in patients with HF. METHODS: The PubMed, 
      Embase, Cochrane Library, and Web of Science databases were systematically 
      searched from database inception to 15 February 2020. Clinical studies of 
      dapagliflozin use in patients with HF were included. Data on HHF, all-cause 
      mortality, cardiovascular death, major adverse cardiovascular events (MACE), 
      systolic blood pressure, body weight, glycated hemoglobin (HbA1c), and adverse 
      events were collected for analysis. RESULTS: Four randomized controlled trials 
      involving 6738 patients with HF were included in this meta-analysis. Patients 
      receiving dapagliflozin showed a significantly lower incidence of HHF [risk ratio 
      (RR) 0.72; P < 0.00001], all-cause mortality (RR 0.83; P = 0.004), cardiovascular 
      death (RR 0.86; P = 0.03), and MACE (RR 0.88; P = 0.03). Moreover, patients 
      receiving dapagliflozin also showed significant improvements in systolic blood 
      pressure and body weight. However, no statistical difference was observed in 
      HbA1c. In addition, hypoglycemia, volume depletion, and renal impairment was not 
      more frequent with dapagliflozin than with placebo. CONCLUSION: This 
      meta-analysis suggests that dapagliflozin could be a therapeutic strategy for 
      patients with HF regardless of the presence or absence of T2DM.
FAU - Zheng, Xiao-Dong
AU  - Zheng XD
AD  - Department of Intensive Care Unit, Suqian First Hospital, Suqian Clinical College 
      of Xuzhou Medical University, Affiliated Hospital of Kangda College of Nanjing 
      Medical University, Suqian, China.
AD  - Department of Critical Care, Suqian Hospital of Chinese Medicine, Affiliated 
      Hospital of Nanjing University of Chinese Medicine, Suqian, Jiangsu, China.
FAU - Qu, Qiang
AU  - Qu Q
AD  - The First Clinical Medical College of Nanjing Medical University, Nanjing, China.
FAU - Jiang, Xing-Yu
AU  - Jiang XY
AD  - The First Clinical Medical College of Nanjing Medical University, Nanjing, China.
FAU - Wang, Zhong-Yuan
AU  - Wang ZY
AD  - The First Clinical Medical College of Nanjing Medical University, Nanjing, China.
FAU - Tang, Cheng
AU  - Tang C
AD  - Department of Intensive Care Unit, Suqian First Hospital, Suqian Clinical College 
      of Xuzhou Medical University, Affiliated Hospital of Kangda College of Nanjing 
      Medical University, Suqian, China.
AD  - Department of Critical Care, Suqian Hospital of Chinese Medicine, Affiliated 
      Hospital of Nanjing University of Chinese Medicine, Suqian, Jiangsu, China.
AD  - The First Clinical Medical College of Nanjing Medical University, Nanjing, China.
FAU - Sun, Jin-Yu
AU  - Sun JY
AD  - The First Clinical Medical College of Nanjing Medical University, Nanjing, China. 
      sunjinyu@njmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201001
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Body Weight
MH  - Cardiovascular Diseases/drug therapy/mortality
MH  - Diabetes Mellitus, Type 2/*drug therapy/epidemiology
MH  - Glucosides/administration & dosage/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin
MH  - Heart Failure/*drug therapy/epidemiology
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2 Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
EDAT- 2020/10/02 06:00
MHDA- 2021/11/05 06:00
CRDT- 2020/10/01 12:15
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/11/05 06:00 [medline]
PHST- 2020/10/01 12:15 [entrez]
AID - 10.1007/s40256-020-00441-x [pii]
AID - 10.1007/s40256-020-00441-x [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2021 May;21(3):321-330. doi: 10.1007/s40256-020-00441-x. 
      Epub 2020 Oct 1.